Effectiveness and Safety of Fulvestrant in Postmenopausal Women With Advanced Breast Cancer HR+, HER2-

Study Overview
=================
Brief Summary
-----------------
A phase IV, single arm study will be performed in postmenopausal women with locally advanced or metastatic breast cancer. All patients included will receive fulvestrant from Dr. Reddy's Laboratories, in accordance with local practice and the regulatory authorization of the drug in Colombia. This study will be carried out for 1 year and approximately 40 patients will be included in 2 research centers selected for its conduct. Patients who meet the inclusion criteria and who do not have to be discarded from entering the study due to meeting any of the exclusion criteria, will be evaluated to determine the effectiveness and tolerability of the administration of Dr. Reddy's fulvestrant at a dose of 500 mg / month plus an additional indicated dose 14 days after the initial dose, for 12 months of follow-up or until disease progression or the appearance of unacceptable toxicity. The assessment of tolerability will be carried out based on the collection of data related to adverse events from the first dose administered.

Official Title
-----------------
Real-world Effectiveness and Safety of a Generic Fulvestrant Alone or in Combination With Cyclin Inhibitors in Postmenopausal Women With Advanced Breast Cancer HR+, HER2-, in Two Colombian Referral Centers

Conditions
-----------------
Breast Neoplasm Female

Intervention / Treatment
-----------------
* Drug: Fulvestrant


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Postmenopausal women (defined as those with permanent cessation of menstruation for more than 12 months, regardless of whether their menopausal condition occurred naturally or was artificially induced), ambulatory or hospitalized Diagnosis of advanced breast cancer HR +, HER2- Positivity for hormone receptors (either estrogen, progesterone, or both). Negative for human epidermal growth factor receptor 2 (HER2). Acceptance of informed consent, if it is required by local regulatory standards. Exclusion Criteria History of previous treatment with fulvestrant. Concomitant treatment with antitumor drugs other than cyclin inhibitors (abemaciclib, palbociclib, ribociclib). Pregnancy. Lactation. Hypersensitivity to any of the excipients included in the complete formulation of fulvestrant from Dr. Reddy's Laboratories Limited. Renal insufficiency grade 4 or 5 (creatinine clearance <30 ml / min / 1.73 m2 according to the classification of the National Kidney Foundation). Hepatic failure (Child-Pugh C stage). Performance status ECOG ≥ 3.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Fulvestrant|Medicine for Advanced breast cancer|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Objective response rate | Objective response rate (ORR), defined as the proportion of patients with a complete response or partial response to treatment according to Response Evaluation Criteria in Solid Tumors (RECIST)percentage of patients with complete response or partial response) according to RECIST 1.1 | Measured at 12 months | 
| Clinical benefit rate (percentage of patients with complete response, partial response and stable disease) | CBR is the proportion of patients with a complete or partial response or with stable disease | Measured at 12 months | 
| Overall survival rate | The percentage of people in a study or treatment group who are still alive for a certain period of time after they were diagnosed with or started treatment for a disease | 12 months | 
| Disease-free survival rate | It is the percentage of individuals in the treatment group who are likely to be free of the signs and symptoms of a disease after a specified duration of time | 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Describe the demographic characteristics of the patients included in the study |  | Measured at 12 months | 
| Assess percentage of patients with adverse events (assessed by CTCAEv4.0) from the first administration and until the end of follow-up. | Common Terminology Criteria for Adverse Events | Measured at 12 months | 
| Assess Percentage of patients with serious adverse events (assessed by CTCAEv4.0) from the first administration to the end of follow-up. | Common Terminology Criteria for Adverse Events | Measured at 12 months | 
| Assess incidence, severity, and relationship to treatment defined by the investigator for reported adverse events. | Common Terminology Criteria for Adverse Events | Measured at 12 months |